Zobrazeno 1 - 10
of 340
pro vyhledávání: '"Huilai Zhang"'
Autor:
Sicong Zhang, Xianming Liu, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianhuo Wang, Huilai Zhang
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 4, Pp 269-273 (2024)
Externí odkaz:
https://doaj.org/article/7de5053494d3482e991966082c39f67d
Autor:
Junlei Jia, Xiaohui Wang, Zheng Song, Shen Meng, Yue Fei, Jingwei Yu, Xia Liu, Xue Han, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Wenchen Gong, Bin Meng, Xiubao Ren, Xianhuo Wang, Huilai Zhang
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 3, Pp 223-229 (2024)
Externí odkaz:
https://doaj.org/article/0e200376c12545268d4cfda6060a3a87
Autor:
Yuankai Shi, Keshu Zhou, Hui Zhou, Yan Qin, Hongmei Jing, Ying Xiang, Zhao Wang, Zhen Wang, Aimin Zang, Ou Bai, Zhenyu Li, Huilai Zhang, Yongping Song, Jinjin Liang, Min Wei
Publikováno v:
EClinicalMedicine, Vol 73, Iss , Pp 102702- (2024)
Summary: Background: MIL62, a novel glycoengineered type Ⅱ anti-CD20 monoclonal antibody, with a nearly completely afucosylated N-glycans in Fc region, has demonstrated superior activity compared with rituximab and obinutuzumab in vitro and in vivo
Externí odkaz:
https://doaj.org/article/2a3c6df3d77e4c00af3f193cded6e60d
Autor:
Hui Li, Peng Liu, Yao Liu, Liang Huang, Yuhua Li, QingQing Cai, Huilai Zhang, Jian-Qing Mi, Zhi Wang, Ting Niu, Dehui Zou, Wenyan Yu, Heng Mei, Jianqiu Wu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Relapsed/refractory (R/R) central nervous system lymphomas (CNSLs) are associated with a poor prognosis. Relmacabtagene autoleucel (relma-cel), expressing the same chimeric antigen receptor (CAR) as lisocabtagene maraleucel, with an optimi
Externí odkaz:
https://doaj.org/article/24bef32138f34ab0902b75cfac321656
Autor:
Yuqin Song, Keshu Zhou, Dehui Zou, Dengju Li, Jianda Hu, Haiyan Yang, Huilai Zhang, Jie Ji, Wei Xu, Jie Jin, Fangfang Lv, Ru Feng, Sujun Gao, Daobin Zhou, Constantine S. Tam, David Simpson, Michael Wang, Tycel J. Phillips, Stephen Opat, Cheng Fang, Shaohui Sun, Jun Zhu
Publikováno v:
Cancer Medicine, Vol 12, Iss 18, Pp 18643-18653 (2023)
Abstract Background We previously reported results of a pooled analysis of two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when zanubrutinib is used in second‐line versus later‐line. Here, we present
Externí odkaz:
https://doaj.org/article/1bc9e62404054e8489c6afc31806b1b4
Autor:
Kaili Zhong, Yanyan Shi, Yuhuan Gao, Huilai Zhang, Mingzhi Zhang, Qiaohua Zhang, Xinan Cen, Mei Xue, Yan Qin, Yu Zhao, Liling Zhang, Rong Liang, Ningju Wang, Yan Xie, Yu Yang, Aichun Liu, Huizheng Bao, Jingwen Wang, Baoping Cao, Wei Zhang, Weijing Zhang
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background This study aimed to compare the efficacy and safety of high-dose methotrexate (HD-MTX) versus teniposide (TEN) in patients with newly diagnosed immunocompetent primary central nervous system lymphomas (PCNSLs). Methods The study i
Externí odkaz:
https://doaj.org/article/e64212ebe785499289b5056df637f01c
Autor:
Yuqin Song, Junning Cao, Qingyuan Zhang, Caixia Li, Lugui Qiu, Junyuan Qi, Huilai Zhang, Wenyu Li, Lihong Liu, Hongmei Jing, Keshu Zhou, Weijing Zhang, Liling Zhang, Daqi Li, Liqun Zou, Haiyan Yang, Wenbin Qian, Hui Zhou, Jianda Hu, Hongyan Yin, Sisi Fu, Songhua Fan, Qian Xu, Jian Wang, Xiaoyun Jia, Guangxiu Dai, Weiguo Su, Jun Zhu
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Sovleplenib (HMPL-523) is a selective spleen tyrosine kinase (Syk) inhibitor with antitumor activity in preclinical models of B-cell malignancy. We conducted a dose-escalation and dose-expansion phase I study of sovleplenib in patients with relapsed/
Externí odkaz:
https://doaj.org/article/2a631b479f3e41d4be020eef1b73030c
Autor:
Lihong Liu, Qingyuan Zhang, Hongtao Song, Yuwei Deng, Huilai Zhang, Xianhuo Wang, Jianli Ma, Xiaosan Zhang, Zirong Zhang, Caili Liu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/890e810e764c4848b080156055bbab9b
Autor:
Tingting Zhang, Weiwei Tian, Shuang Wei, Xinyi Lu, Jing An, Shaolong He, Jie Zhao, Zhilin Gao, Li Li, Ke Lian, Qiang Zhou, Huilai Zhang, Liang Wang, Liping Su, Huicong Kang, Ting Niu, Ailin Zhao, Jing Pan, Qingqing Cai, Zhenshu Xu, Wenming Chen, Hongmei Jing, Peng Li, Wanhong Zhao, Yang Cao, Jianqing Mi, Tao Chen, Yuan Chen, Ping Zou, Veronika Lukacs-Kornek, Christian Kurts, Jian Li, Xiansheng Liu, Qi Mei, Yicheng Zhang, Jia Wei
Publikováno v:
Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-17 (2023)
Abstract The outbreak of coronavirus disease 2019 (COVID-19) posed an unprecedented challenge on public health systems. Despite the measures put in place to contain it, COVID-19 is likely to continue experiencing sporadic outbreaks for some time, and
Externí odkaz:
https://doaj.org/article/317083c379354394bdbd8c7877d9e996
Autor:
Ping Li, Yang Liu, Yun Liang, Jian Bo, Sujun Gao, Yongxian Hu, Yu Hu, He Huang, Xiaojun Huang, Hongmei Jing, Xiaoyan Ke, Jianyong Li, Yuhua Li, Qifa Liu, Peihua Lu, Heng Mei, Ting Niu, Yongping Song, Yuqin Song, Liping Su, Sanfang Tu, Jianxiang Wang, Depei Wu, Zhao Wang, Kailin Xu, Zhitao Ying, Qingming Yang, Yajing Zhang, Fengxia Shi, Bin Zhang, Huilai Zhang, Xi Zhang, Mingfeng Zhao, Weili Zhao, Xiangyu Zhao, Liang Huang, Jun Zhu, Wenbin Qian, Weidong Han, Aibin Liang
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 2, Pp 129-146 (2023)
Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in
Externí odkaz:
https://doaj.org/article/9444c9c2b3e5428698211ae089d3471a